Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 7,071 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasms Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery

NCT04554316
View directory record Official record
Conditions
Scar, Breast Neoplasms, Breast Diseases, Surgical Wound
Interventions
Steri-strip
Device
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
East Norriton, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 21, 2026, 1:03 AM EDT
Recruiting Phase 2 Interventional

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

NCT04329065
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Paclitaxel, Trastuzumab, Pertuzumab, Docetaxel, Carboplatin, Ultrasound Imaging, Biopsy Procedure, Biospecimen Collection
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer

NCT00093834
View directory record Official record
Conditions
Breast Cancer
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, cyclophosphamide, doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 21, 2026, 1:03 AM EDT
Withdrawn Phase 1 Interventional

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

NCT05655598
View directory record Official record
Conditions
Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer
Interventions
Palbociclib Oral Product, TAS-116
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy

NCT00540852
View directory record Official record
Conditions
Breast Cancer
Interventions
Diffuse Optical Spectroscopy Imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 21, 2026, 1:03 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer

NCT01389830
View directory record Official record
Conditions
Advanced Cancers
Interventions
Telephone Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 21, 2026, 1:03 AM EDT
Not listed No phase listed Observational

Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17

NCT00897065
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, polymerase chain reaction, protein expression analysis, diagnostic laboratory biomarker analysis, fluorescent antibody technique, immunohistochemistry staining method, immunologic technique
Genetic · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Female only
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 21, 2026, 1:03 AM EDT
Withdrawn Not applicable Interventional

Study to Assess Breast Sensation Before and After Breast Cancer Treatment

NCT02817607
View directory record Official record
Conditions
Breast Reconstruction, Ductal Carcinoma In-situ
Interventions
Sensory testing and Biopsy
Procedure
Lead sponsor
Duke University
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Not applicable Interventional

A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ

NCT01628536
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Black cohosh
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 21, 2026, 1:03 AM EDT
Not listed Phase 1 Interventional

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

NCT02950064
View directory record Official record
Conditions
Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
BTP-114
Drug
Lead sponsor
Placon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

NCT00503906
View directory record Official record
Conditions
Breast Cancer
Interventions
Avastin, Gemcitabine, Abraxane
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of One-port and Two-port Tissue Expanders for Breast Reconstruction

NCT02725801
View directory record Official record
Conditions
Breast Cancer
Interventions
Allergen one-port tissue expander placement, AlloX2 two-port tissue expander placement
Device
Lead sponsor
Lesley Wong
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 21, 2026, 1:03 AM EDT
Terminated Not applicable Interventional

Preventing Lymphedema in Axillary Lymph Node Dissection

NCT03428581
View directory record Official record
Conditions
Lymphedema, Breast Cancer, Melanoma
Interventions
ALND with ARM +/- LVB, ALND
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery

NCT05583981
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Interview
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 21, 2026, 1:03 AM EDT
Recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors

NCT07120100
View directory record Official record
Conditions
Breast Cancer Female, Gynecologic Cancer
Interventions
rTMS
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Active, not recruiting Not applicable Interventional

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

NCT04030507
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Interventions
MRI
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

NCT03307044
View directory record Official record
Conditions
Breast Carcinoma, Cancer Survivor, Cervical Carcinoma, Dyspareunia, Vaginal Dryness
Interventions
Laser Therapy, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Interventions
XmAb®808, Keytruda® (pembrolizumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 21, 2026, 1:03 AM EDT
Not listed Phase 2 Interventional

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

NCT03961698
View directory record Official record
Conditions
Breast Cancer, Renal Cell Carcinoma
Interventions
IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 21, 2026, 1:03 AM EDT
Completed No phase listed Observational

Microarray Analysis for Human Genetic Disease

NCT00001898
View directory record Official record
Conditions
Breast Neoplasm, Hereditary Neoplastic Syndrome, Melanoma, Ovarian Neoplasm
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
5
States / cities
Tucson, Arizona • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 1:03 AM EDT
Recruiting No phase listed Observational

Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai

NCT07220863
View directory record Official record
Conditions
Breast Cancer Awareness
Interventions
Not listed
Lead sponsor
Feminai
Industry
Eligibility
25 Years to 75 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 21, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)

NCT05528263
View directory record Official record
Conditions
Acupuncture, Early-stage Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
Acupuncture, Nature scenery with a relaxation exercise
Device · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 1:03 AM EDT
Terminated Not applicable Interventional

Acupressure for Pain and Opioid Use Among Breast Cancer Patients

NCT03655600
View directory record Official record
Conditions
Breast Cancer, Fatigue, Chronic Pain
Interventions
Self-administered acupressure
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 21, 2026, 1:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258464
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 21, 2026, 1:03 AM EDT